

System Variance Model for SPECT Ioflupane


Anne Smith and Johannes Zeintl

Siemens Molecular Imaging

Systems Engineering


November 20th, 2015

QIBA's Mission



System Variance Sources Model – Ioflupane SPECT



Each source contributes variance to final measurement and ideally should be measured/controlled



*if SPECT/CT or CT image used for attenuation correction

Quantify & Rank the Variance Contribution (example ranking only)


Higher the ranking → more effort needed in Profile to decrease or control (“biggest band for the buck”)



*if SPECT/CT or CT image used for attenuation correction

PET FDG Tumor & Amyloid Strategies to Control Variance

Relied heavily on PET clinical trial harmonization experience from pharma and CROs



Sources of data to determine variance


- Scientific literature
 - Analyze data in published studies
 - If possible, acquire the data reported on in the literature
- Phantom studies
 - “Ground truth” is known with certainty
- Pilot studies
 - QIBA has funded several of these
- Manufacturers’ Specifications
 - Accuracy

Excellent Example to Estimate Various Sources of Variance


- Following four slides were contributed by Brian Zimmerman from NIST
 - Presented Nov. 17th in the Phantom/DRO Sub-group Netmeeting
- Studies like this can help us quantify and rank our sources of variance
- Note where gaps of data/scientific studies are for quantifying variance contribution
 - Develop projects and request funding (e.g. from QIBA) to fill in gaps

SPECT imaging quantification with surrogates

- Series of ^{133}Ba sources designed and calibrated by NIST (constructed by private company)
- Diameters varied from 0.8 cm to 2.9 cm to test partial volume recovery
- Sources sent to 9 clinics in different countries (usually representing best practice in country); half of participants from developing countries
- Uncertainty on activity calibration < 1 %



Three trials




- First: use of “best practice”
- Second: Strict, prescriptive protocol
- Third: Analysis of second trial data by single center
- Study used combination of Planar and SPECT-CT

Best results achieved with prescriptive protocol and centralized data analysis

Justification for our QIBA BC ☺ !




- Average recovery using SPECT-CT improved from +12(6) % in first trial to 0(8) %
- Partial volume corrections of up to 20 % required (not made in comparison)
- Quantification of 5 % should be possible with appropriate corrections and protocol



SPECT-CT results: ratio of participants' results to NIST-calibrated activity for each test object

What about this case?

- ^{57}Co as surrogate for ^{123}I ?
 - Strongest photons in ^{123}I at 158 keV; doublet in ^{57}Co decay at ~ 125 keV
- With help from source manufacturer, making solid mock sources with any of these configurations should be possible (even with different activity levels)
- Calibrated activity uncertainty should be on order of 1 %



Flangeless Esser PET Phantom Lid™



Flangeless Esser PET Phantom™